Get a free sample of Cancer Supportive Care Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Cancer Supportive Care Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Cancer Supportive Care Drugs Market Size
Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.
The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.
Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.
How big is the cancer supportive care drugs market?
Global market for cancer supportive care drugs was worth USD 14.4 billion in 2022 and is estimated to expand at 1.9% CAGR from 2023-2032 attributed to the growing progress in cancer treatments, such aschemotherapy, radiation therapy, targeted therapy, and immunotherapy.
Why is the demand for G-CSFs gaining traction in the cancer supportive care drugs industry?
The G-CSFs (granulocyte-colony stimulating factors) segment accounted for 22.8% share in the cancer-supportive care drugs market owing to its extensive usage to avoid neutropenia.
Which are the top firms operating in the cancer supportive care drugs market?
Some of the top companies in the industry are Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Teva Pharmaceuticals Industries Ltd., and Fagron Group.
What is the size of the Asia Pacific cancer supportive care drugs industry?
Asia Pacific industry is set to witness 2.3% CAGR from 2023-2032 and reach USD 6.1 billion by 2032 driven by the rising incidence of cancer due to population growth, aging, changing lifestyles, and environmental factors.